Gruppo guidato da Alessandro Vercelli
Born in Battipaglia on 14.04.1991 - Italian.
Current position
Postdoctoral Position in Professor Alessandro Vercelli’s group “Brain development and disease” at Neuroscience Institute Cavalieri Ottolenghi, Regione Gonzole 10, 10043 Orbassano (TO) - Italy
Education
2020: PhD in Cellular and Molecular Biology –PhD Thesis Dissertation: “Involvement of the Alterations of GABA Catabolism and Oxidative Stress in Mitochondrial Damage associated with Neurological Disorders and Neurodegeneration” (Judgment: Excellent quality), University of Rome Tor Vergata, Italy.
2017- Qualification to the Profession of Specialist Biologist – University of Rome Tor Vergata, Italy.
2016: Master’s degree in Cellular and Molecular Biology – Experimental thesis in Molecular Neurobiology: "The FMRP-RNF10 Axis: Stress Response and Cell Plasticity" (final grade: 110 cum laude/110), University of Rome Tor Vergata, Italy.
2014: Bachelor’s degree in Biological Sciences (Molecular Biology curriculum)-Bibliographic thesis in Human Anatomy"The Nerve Growth Factor: Moderni Orizzonti", PI: Professor Stefania Lucia Nori; Department of Biology– University of Salerno, Italy.
Previous positions
2020 - up to now. Post-doc Fellow, Department of Neuroscience Rita Levi Montalcini and Neuroscience Institute Cavalieri Ottolenghi (NICO), University of Turin, Italy. PI: ProfessorsAlessandro Vercelli and Marina Boido.
2016-2019: PhD Student in Cellular and Molecular Biology, Department of Biology– University of Rome Tor Vergata.PI: Professors Luisa Rossi and Patrizia Malaspina.
2014-2015: Master’s Degree studentin Cellular and Molecular Biology – Internship in the Molecular NeurobiologyLaboratory, Department of Biomedicine of the Medicine Faculty University of Rome Tor Vergata, Italy- PI: Professors Claudia Bagni, Laura Pacini and Stefano Rufini.
Publications:
News
Riposizionamento dei farmaci: la moxifloxacina, un antibiotico potrebbe fermare la SMA
La moxifloxacina, antibiotico ampiamente utilizzato per la cura di infezioni respiratorie, risulta efficace anche nel trattamento della SMA. Lo dimostra uno studio realizzato dalle ricercatrici NICO Marina Boido e Giovanna Menduti in collaborazione con l’Università di Valencia e l’Institut National de la Santé Et de la Recherche Médicale, e grazie al supporto di AFM-Téléthon.
I risultati - pubblicati su Cellular and Molecular Life Sciences e presentati a SMA Europe (Barcellona, 21-23 ottobre 2022) confermano come il riposizionamento dei farmaci sia una strategia preziosa per identificare nuove terapie per le malattie rare.